Orhan Altay1, Hidenori Suzuki1, Yu Hasegawa1, Bilge Nur Altay2, Jiping Tang1, John H Zhang3. 1. Departments of Physiology, Loma Linda University School of Medicine, Loma Linda, USA. 2. Departments of Physiology, Loma Linda University School of Medicine, Loma Linda, USA; Lokman Hekim University School of Medicine, Ankara, Turkey. 3. Departments of Physiology, Loma Linda University School of Medicine, Loma Linda, USA; Departments of Neurosurgery, Loma Linda University School of Medicine, Loma Linda, USA. Electronic address: johnzhang3910@yahoo.com.
Abstract
BACKGROUND: Sphingosine kinase (SphK) 1 has been reported as an important signaling node in anti-apoptotic signaling. Heparin is a pleiotropic drug that antagonizes many pathophysiological mechanisms. In this study, we evaluated if heparin prevents early brain injury (EBI) after subarachnoid hemorrhage (SAH) by anti-apoptotic mechanisms including SphK1. METHODS: SAH was induced by endovascular perforation in mice, which were randomly assigned to sham-operated (n = 23), SAH + vehicle (n = 36), SAH + 10U heparin pretreatment (n = 13), SAH + 30U heparin pretreatment (n = 15), SAH + 10U heparin posttreatment (n = 31), and SAH + 30U heparin posttreatment (n = 23). At 24 hours post-SAH, neurological scores, brain water content and Evans blue extravasation were evaluated. Also, the expression of SphK, phosphorylated Akt, and cleaved caspase-3 was determined by Western blotting, and cell death was examined by terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate-biotin nick end-labeling staining. RESULTS: Low-dose heparin posttreatment improved neurobehavioral function, brain edema, blood-brain barrier disruption and cell death in the cortex, associated with an increase in SphK1 and phosphorylated Akt, and a decrease in cleaved caspase-3. High-dose heparin had a tendency for increased SAH severity, which obscured the neuroprotective effects by heparin. CONCLUSIONS: Low-dose heparin posttreatment may decrease the development of post-SAH EBI through anti-apoptotic mechanisms including sphingosine-related pathway activation.
BACKGROUND:Sphingosine kinase (SphK) 1 has been reported as an important signaling node in anti-apoptotic signaling. Heparin is a pleiotropic drug that antagonizes many pathophysiological mechanisms. In this study, we evaluated if heparin prevents early brain injury (EBI) after subarachnoid hemorrhage (SAH) by anti-apoptotic mechanisms including SphK1. METHODS:SAH was induced by endovascular perforation in mice, which were randomly assigned to sham-operated (n = 23), SAH + vehicle (n = 36), SAH + 10U heparin pretreatment (n = 13), SAH + 30U heparin pretreatment (n = 15), SAH + 10U heparin posttreatment (n = 31), and SAH + 30U heparin posttreatment (n = 23). At 24 hours post-SAH, neurological scores, brain water content and Evans blue extravasation were evaluated. Also, the expression of SphK, phosphorylated Akt, and cleaved caspase-3 was determined by Western blotting, and cell death was examined by terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate-biotin nick end-labeling staining. RESULTS: Low-dose heparin posttreatment improved neurobehavioral function, brain edema, blood-brain barrier disruption and cell death in the cortex, associated with an increase in SphK1 and phosphorylated Akt, and a decrease in cleaved caspase-3. High-dose heparin had a tendency for increased SAH severity, which obscured the neuroprotective effects by heparin. CONCLUSIONS: Low-dose heparin posttreatment may decrease the development of post-SAH EBI through anti-apoptotic mechanisms including sphingosine-related pathway activation.
Authors: Petra Henrich-Noack; Monika Riek-Burchardt; Kathrin Baldauf; Georg Reiser; Klaus G Reymann Journal: Brain Res Date: 2006-01-03 Impact factor: 3.252
Authors: M P Reilly; S M Taylor; N K Hartman; G M Arepally; B S Sachais; D B Cines; M Poncz; S E McKenzie Journal: Blood Date: 2001-10-15 Impact factor: 22.113
Authors: Kenneth C-W Yu; Christopher David; Sujata Kadambi; Andreas Stahl; Ken-Ichi Hirata; Tatsuro Ishida; Thomas Quertermous; Allen D Cooper; Sungshin Y Choi Journal: J Lipid Res Date: 2004-06-01 Impact factor: 5.922
Authors: Panagiota Zania; Matthew Papaconstantinou; Christodoulos S Flordellis; Michael E Maragoudakis; Nikos E Tsopanoglou Journal: Am J Physiol Cell Physiol Date: 2008-03-26 Impact factor: 4.249
Authors: Kumlesh K Dev; Florian Mullershausen; Henri Mattes; Rainer R Kuhn; Graeme Bilbe; Daniel Hoyer; Anis Mir Journal: Pharmacol Ther Date: 2007-09-08 Impact factor: 12.310